Cargando…
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing’s sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy
The aim of the present study was to determine the usefulness of a patient-derived orthotopic xenograft (PDOX) nude-mouse model of a doxorubicin-resistant metastatic Ewing’s sarcoma, with a unique combination of a FUS-ERG fusion and CDKN2A deletion, to identify effective drugs for third-line chemothe...
Autores principales: | Miyake, Kentaro, Murakami, Takashi, Kiyuna, Tasuku, Igarashi, Kentaro, Kawaguchi, Kei, Miyake, Masuyo, Li, Yunfeng, Nelson, Scott D., Dry, Sarah M., Bouvet, Michael, Elliott, Irmina A., Russell, Tara A., Singh, Arun S., Eckardt, Mark A., Hiroshima, Yukihiko, Momiyama, Masashi, Matsuyama, Ryusei, Chishima, Takashi, Endo, Itaru, Eilber, Fritz C., Hoffman, Robert M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732717/ https://www.ncbi.nlm.nih.gov/pubmed/29262551 http://dx.doi.org/10.18632/oncotarget.20789 |
Ejemplares similares
-
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model
por: Murakami, Takashi, et al.
Publicado: (2016) -
Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model
por: Kiyuna, Tasuku, et al.
Publicado: (2018) -
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
por: Murakami, Takashi, et al.
Publicado: (2017) -
Efficacy of Tumor-Targeting Salmonella typhimurium A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models
por: Murakami, Takashi, et al.
Publicado: (2019) -
Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations
por: Miyake, Kentaro, et al.
Publicado: (2018)